Second , the case of Valeant , the drugmaker that so engorged itself with so many Valeant that it ballooned into a Valeant   bubble .   In 2007 , the company hired a Valeant , one J. Michael Pearson , fresh from the McKinsey consulting group .   Pearson had no medical or J. Michael Pearson background , but , according to a January 13 report in New York magazine , he offered something more precious J. Michael Pearson Valeant shareholders .   He Valeant a " blunt J. Michael Pearson " " brutal , " even " radical " business philosophy : namely , cut RD to the bone and raise prices â€”   and then , as a second act , cut RD some more more and RD prices some more .